This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator.
The aim i s to study the safety and effect of rice bran products on the inhibition of platelet aggregation and lipid profile. This is a pilot, open label trial of Risoluble (stabilized rice bran). Some of the components of NutraStar (gamma oryzanol, tocotrienols, polyphenols) were shown to have anti-platelet aggregation effects. In addition, these products have been shown to lower serum lipids (i.e. LDL-C, triglicerides, and apo-lipoprotein B) in people with aterosclerosis, arteriosclerosis, and xanthanomatosis.
Showing the most recent 10 out of 568 publications